
Danaher Corporation DHR
€ 156.92
0.42%
Geschäftsbericht 2025
hinzugefügt 24.02.2026
Danaher Corporation Langfristige Verbindlichkeiten 2011-2026 | DHR
Langfristige Verbindlichkeiten Jährlich Danaher Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 26.9 B | 14.8 B | 15.5 B | 15.3 B | 18.3 B | 8.15 B | 7.69 B | 9.65 B | 8.81 B |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 26.9 B | 7.69 B | 13.9 B |
Langfristige Verbindlichkeiten anderer Aktien in der Diagnostik & Forschung
| Name | Langfristige Verbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Enzo Biochem
ENZ
|
4.6 M | - | -8.98 % | $ 14.8 K | ||
|
Centogene N.V.
CNTG
|
23.7 M | - | -6.23 % | $ 30.6 M | ||
|
Heska Corporation
HSKA
|
57.9 M | - | - | $ 1.31 B | ||
|
DermTech
DMTK
|
865 K | - | -11.32 % | $ 2.94 M | ||
|
Quest Diagnostics Incorporated
DGX
|
5.17 B | $ 202.99 | 0.4 % | $ 22.5 B | ||
|
Celcuity
CELC
|
69.2 K | $ 87.91 | -0.37 % | $ 4.11 B | ||
|
Akumin
AKU
|
527 M | - | -17.87 % | $ 25.9 M | ||
|
Co-Diagnostics
CODX
|
574 K | $ 3.88 | 2.64 % | $ 5.16 M | ||
|
Castle Biosciences
CSTL
|
2.76 M | $ 20.78 | 0.58 % | $ 602 M | ||
|
Aspira Women's Health
AWH
|
3.49 M | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
134 M | - | -61.36 % | $ 2.46 M | ||
|
Fulgent Genetics
FLGT
|
2.26 M | $ 17.89 | -2.53 % | $ 551 M | ||
|
Biocept
BIOC
|
11.3 M | - | -13.05 % | $ 7.29 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
7.74 M | - | - | $ 562 M | ||
|
Guardant Health
GH
|
91.4 M | $ 131.46 | 1.26 % | $ 16.5 B | ||
|
CareDx, Inc
CDNA
|
17.9 M | $ 24.72 | 2.66 % | $ 1.32 B | ||
|
Chembio Diagnostics
CEMI
|
24.8 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
16 K | - | - | $ 9.42 M | ||
|
ICON Public Limited Company
ICLR
|
461 M | $ 145.31 | -1.63 % | $ 11.4 B | ||
|
Interpace Biosciences
IDXG
|
10 M | $ 1.66 | 5.14 % | $ 7.34 M | ||
|
Illumina
ILMN
|
2.04 B | $ 165.9 | -0.6 % | $ 25.7 B | ||
|
HTG Molecular Diagnostics
HTGM
|
4.1 M | - | -20.0 % | $ 1.06 M | ||
|
Global Cord Blood Corporation
CO
|
2.53 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
131 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
161 K | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
37.1 M | - | 0.12 % | $ 80.1 M | ||
|
Lantheus Holdings
LNTH
|
225 M | $ 104.93 | 0.24 % | $ 7.08 B | ||
|
Charles River Laboratories International
CRL
|
2.35 B | $ 186.66 | -0.96 % | $ 9.25 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
1.43 B | - | - | $ 10.7 B | ||
|
Medpace Holdings
MEDP
|
73.8 M | $ 459.78 | -1.65 % | $ 13.3 B | ||
|
Mettler-Toledo International
MTD
|
1.61 B | $ 1 153.27 | -0.1 % | $ 23.8 B | ||
|
Exact Sciences Corporation
EXAS
|
981 M | - | - | $ 19.8 B | ||
|
NeoGenomics
NEO
|
435 M | $ 10.85 | -2.16 % | $ 1.39 B | ||
|
National Research Corporation
NRC
|
39.6 M | $ 17.87 | -2.4 % | $ 400 M | ||
|
Myriad Genetics
MYGN
|
107 M | $ 4.36 | 0.81 % | $ 404 M | ||
|
Natera
NTRA
|
124 M | $ 219.96 | 1.38 % | $ 30.1 B | ||
|
Pacific Biosciences of California
PACB
|
43.9 M | $ 1.38 | 4.55 % | $ 414 M | ||
|
Personalis
PSNL
|
639 K | $ 10.12 | 3.37 % | $ 903 M | ||
|
Koninklijke Philips N.V.
PHG
|
8.45 B | $ 26.89 | 0.75 % | $ 25.5 B | ||
|
Senseonics Holdings
SENS
|
163 M | $ 7.31 | 0.97 % | $ 305 M | ||
|
QIAGEN N.V.
QGEN
|
1.99 B | - | - | $ 10.6 B | ||
|
Soleno Therapeutics
SLNO
|
10.8 M | - | - | $ 2.69 B | ||
|
Biomerica
BMRA
|
1.57 M | $ 1.94 | -3.0 % | $ 4.46 M | ||
|
Twist Bioscience Corporation
TWST
|
4.56 M | $ 85.49 | 5.82 % | $ 5.11 B | ||
|
Laboratory Corporation of America Holdings
LH
|
7.82 B | $ 264.64 | -0.15 % | $ 22 B | ||
|
Thermo Fisher Scientific
TMO
|
22.5 B | $ 473.07 | -0.14 % | $ 178 B | ||
|
Trinity Biotech plc
TRIB
|
106 M | $ 0.6 | -10.82 % | $ 216 M | ||
|
Motus GI Holdings
MOTS
|
2.16 M | - | -34.28 % | $ 263 K | ||
|
Neogen Corporation
NEOG
|
19.6 M | $ 9.48 | 1.88 % | $ 2.06 B | ||
|
Invitae Corporation
NVTA
|
320 M | - | - | $ 21.2 M |